Ensemble Docking Approach to Mitigate Pregnane X Receptor-Mediated CYP3A4 Induction Risk

被引:0
|
作者
Chen, Qi [5 ]
Zhou, Xin [1 ]
Rehmel, Jessica [1 ]
Steele, James P. [2 ]
Svensson, Kjell A. [3 ]
Beck, James P. [4 ]
Hembre, Erik J. [5 ]
Hao, Junliang [4 ]
机构
[1] Eli Lilly & Co, Lilly Biotechnol Ctr, Drug Disposit, San Diego, CA 92121 USA
[2] Eli Lilly & Co, Lilly Biotechnol Ctr, Quantitat Biol, San Diego, CA 92121 USA
[3] Eli Lilly & Co, Lilly Biotechnol Ctr, Neurosci Discovery, San Diego, CA 92121 USA
[4] Eli Lilly & Co, Lilly Biotechnol Ctr, Discovery Chem Res & Technol, San Diego, CA 92121 USA
[5] Eli Lilly & Co, Lilly Res Labs, Discovery Chem Res & Technol, Indianapolis, IN 46285 USA
关键词
INHIBITORS OPTIMIZING POTENCY; SUBTYPE-SELECTIVE AGENTS; POTENTIAL THERAPEUTICS; COACTIVATOR BINDING; CRYSTAL-STRUCTURE; RECENT PROGRESS; PXR; DISCOVERY; COMPLEX; SULFONAMIDES;
D O I
10.1021/acs.jcim.2c01175
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Three structurally closely related dopamine D1 receptor positive allosteric modulators (D1 PAMs) based on a tetrahydroisoquinoline (THIQ) scaffold were profiled for their CYP3A4 induction potentials. It was found that the length of the linker at the C5 position greatly affected the potentials of these D1 PAMs as CYP3A4 inducers, and the level of induction correlated well with the activation of the pregnane X receptor (PXR). Based on the published PXR X-ray crystal structures, we built a binding model specifically for these THIQ-scaffold-based D1 PAMs in the PXR ligand-binding pocket via an ensemble docking approach and found the model could explain the observed CYP induction disparity. Combined with our previously reported D1 receptor homology model, which identified the C5 position as pointing toward the solvent-exposed space, our PXR-binding model coincidentally suggested that structural modifications at the C5 position could productively modulate the CYP induction potential while maintaining the D1 PAM potency of these THIQ-based PAMs.
引用
收藏
页码:173 / 186
页数:14
相关论文
共 50 条
  • [31] Inhibition of CYP3A4 expression by camptothecin via blocking activation of pregnane X receptor
    Chen, Yakun
    Tang, Yong
    Robbins, Gregory Thomas
    Nie, Daotai
    CANCER RESEARCH, 2010, 70
  • [32] Differential Effect of Liver Cirrhosis on the Pregnane X Receptor-Mediated Induction of CYP3A1 and 3A2 in the Rat
    De Martin, Sara
    Gabbia, Daniela
    Albertin, Giovanna
    Sfriso, Maria Martina
    Mescoli, Claudia
    Albertoni, Laura
    Paliuri, Giovanna
    Bova, Sergio
    Palatini, Pietro
    DRUG METABOLISM AND DISPOSITION, 2014, 42 (10) : 1617 - 1626
  • [33] Metformin suppresses pregnane X receptor (PXR)-regulated transactivation of CYP3A4 gene
    Krausova, Lucie
    Stejskaova, Lucie
    Wang, Hongwei
    Vrzal, Radim
    Dvorak, Zdenek
    Mani, Sridhar
    Pavek, Petr
    BIOCHEMICAL PHARMACOLOGY, 2011, 82 (11) : 1771 - 1780
  • [34] Rifampicin-Activated Human Pregnane X Receptor and CYP3A4 Induction Enhance Acetaminophen-Induced Toxicity
    Cheng, Jie
    Ma, Xiaochao
    Krausz, Kristopher W.
    Idle, Jeffrey R.
    Gonzalez, Frank J.
    DRUG METABOLISM AND DISPOSITION, 2009, 37 (08) : 1611 - 1621
  • [35] Induction of CYP3A4 by omeprazole and lansoprazole enantiomers in human hepatocytes and cell lines via glucocorticoid receptor and pregnane X receptor axis
    Novotna, A.
    Dvorak, Z.
    TOXICOLOGY LETTERS, 2015, 238 (02) : S146 - S146
  • [36] The effect of pregnane X receptor (PXR)-mediated CYP3A induction on acetaminophen hepatotoxicity
    Ma, Xiaochao
    Chen, Chi
    Shah, Yatrik
    Morimura, Keiichirou
    Krausz, Kristopher W.
    Idle, Jeffrey R.
    Gonzalez, Frank J.
    FASEB JOURNAL, 2007, 21 (06): : A1184 - A1184
  • [37] Endosulfan-a induces CYP2B6 and CYP3A4 by activating the pregnane x receptor
    Lively, Erin A.
    Schmidt, Nissa L.
    Casabai, Richard C. T.
    Wallace, Andrew D.
    Gardiner, Catherine S.
    DeKrey, Gregory K.
    FASEB JOURNAL, 2007, 21 (06): : A1183 - A1183
  • [38] Novel ligands for human pregnane X receptor differentially regulate CYP3A4 promoter activity
    Banerjee, Monimoy
    Chen, Taosheng
    FASEB JOURNAL, 2014, 28 (01):
  • [39] Evaluation of Cynomolgus Monkey Pregnane X Receptor, Primary Hepatocyte, and in Vivo Pharmacokinetic Changes in Predicting Human CYP3A4 Induction
    Kim, Sean
    Dinchuk, Joseph E.
    Anthony, Monique N.
    Orcutt, Tami
    Zoeckler, Mary E.
    Sauer, Mary B.
    Mosure, Kathleen W.
    Vuppugalla, Ragini
    Grace, James E., Jr.
    Simmermacher, Jean
    Dulac, Heidi A.
    Pizzano, Jennifer
    Sinz, Michael
    DRUG METABOLISM AND DISPOSITION, 2010, 38 (01) : 16 - 24
  • [40] Sesamin: A Naturally Occurring Lignan Inhibits CYP3A4 by Antagonizing the Pregnane X Receptor Activation
    Lim, Yun-Ping
    Ma, Chia-Yun
    Liu, Cheng-Ling
    Lin, Yu-Hsien
    Hu, Miao-Lin
    Chen, Jih-Jung
    Hung, Dong-Zong
    Hsieh, Wen-Tsong
    Huang, Jin-Ding
    EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE, 2012, 2012